1: Br J Ophthalmol. 2010 Mar 4; [Epub ahead of print] 

Vision screening in a primary care setting.

Silvester AJ.

PMID: 20203085  [PubMed - as supplied by publisher]

2: Br J Ophthalmol. 2010 Feb;94(2):267-8. 

Endothelial cells analysis after intravitreal ranibizumab (Lucentis) in
age-related macular degeneration treatment: a pilot study.

Perez-Rico C, Benitez-Herreros J, Castro-Rebollo M, Gomez-SanGil Y, Germain F,
Montes-Mollon MA, Teus MA.

Publication Types:
    Letter
    Research Support, Non-U.S. Gov't

PMID: 20139298  [PubMed - indexed for MEDLINE]

3: Br J Ophthalmol. 2010 Feb;94(2):265-7. 

Neurodevelopmental outcomes with congenital ocular motor apraxia.

Grigorian AP, Fray KJ, Brodsky MC, Phillips PH.

Publication Types:
    Letter
    Research Support, Non-U.S. Gov't

PMID: 20139297  [PubMed - indexed for MEDLINE]

4: Br J Ophthalmol. 2010 Feb;94(2):263, 265-6. 

Presence of paravascular lamellar holes in patients with idiopathic premacular
fibrosis.

Shimada N, Ohno-Matsui K, Yoshida T, Mochizuki M.

Publication Types:
    Letter
    Research Support, Non-U.S. Gov't

PMID: 20139296  [PubMed - indexed for MEDLINE]

5: Br J Ophthalmol. 2010 Feb;94(2):262-4. 

In vivo corneal confocal microscopic findings and gene analysis of three
patients with Thiel-Behnke corneal dystrophy.

Chen YJ, Chen JT, Lu DW, Tai MC.

Publication Types:
    Case Reports
    Letter

PMID: 20139295  [PubMed - indexed for MEDLINE]

6: Br J Ophthalmol. 2010 Feb;94(2):261-2. 

Primary epithelioid haemangioendothelioma of the eyelid.

Tsuji H, Kanda H, Kashiwagi H, Mimura T.

Publication Types:
    Case Reports
    Letter

PMID: 20139294  [PubMed - indexed for MEDLINE]

7: Br J Ophthalmol. 2010 Feb;94(2):260-1. 

Management of submacular haemorrhage in age-related macular degeneration with
intravitreal tenecteplase.

McAllister IL, Chen SD, Patel JI, Fleming BL, Yu DY.

Publication Types:
    Clinical Trial
    Letter
    Research Support, Non-U.S. Gov't

PMID: 20139293  [PubMed - indexed for MEDLINE]

8: Br J Ophthalmol. 2010 Feb;94(2):236-40. 

Photorefractive keratectomy for the treatment of purely refractive accommodative
esotropia: 6 years' experience.

Hutchinson AK, Serafino M, Nucci P.

The Department of Ophthalmology, Emory University School of Medicine, Atlanta,
Georgia, USA. amy.hutchinson@emory.edu

AIMS: To report the long term outcomes of photorefractive keratectomy (PRK) for
the treatment of hyperopia associated with purely refractive accommodative
esotropia. METHODS: This study was a retrospective chart review of 40 patients
aged 17-39 years who underwent PRK to eliminate their dependence on glasses.
Pre- and postoperative best spectacle corrected visual acuity (BSCVA),
uncorrected visual acuity (UCVA), refractive spherical equivalent (SEQ), ocular
alignment and stereoacuity were reviewed. RESULTS: Forty patients (80 eyes) with
a mean age of 27.9 years were treated for a mean preoperative SEQ of +3.06 D
hyperopia. The mean final postoperative SEQ was +0.06 D. Preoperative BSCVA was
0.04 logarithm of the minimum angle of resolution (logMAR), and did not change
postoperatively. Mean UCVA significantly improved from 0.30 logMAR
preoperatively to 0.08 logMAR post-operatively. Mean pre-operative esotropia at
distance and near was 18.6 prism D. All patients were orthophoric without
correction at the 1 month, 1 year and final postoperative evaluations. Visual
acuity, refractive error and alignment remained stable after the 1 year
postoperative examination. Stereoacuity was unchanged in 80% of patients
postoperatively. There were no complications. CONCLUSION: PRK can be used to
treat low to moderate hyperopia associated with purely refractive accommodative
esotropia in young adults.

Publication Types:
    Evaluation Studies
    Research Support, Non-U.S. Gov't

PMID: 20139292  [PubMed - indexed for MEDLINE]

9: Br J Ophthalmol. 2010 Feb;94(2):223-8. 

Vision self-management for older adults: a randomised controlled trial.

Girdler SJ, Boldy DP, Dhaliwal SS, Crowley M, Packer TL.

Centre for Research into Disability and Society within the Curtin Health
Innovation Research Institute, Curtin University of Technology, Perth,
Australia.

BACKGROUND/AIMS: Ageing of the population will result in unprecedented numbers
of older adults living with age-related vision loss (ARVL). Self-management
models improve health outcomes and reduce healthcare costs; however, the
principles have rarely been applied in low vision services. METHODS: A two-armed
randomised controlled trial of older adults (n=77) with ARVL compared 'usual
care' provided by a not-for-profit community agency with an extended model of
care (usual care+self-management group intervention). The primary outcome
variable (participation in life situations) was measured using the Activity Card
Sort. Secondary outcome measures examined general health and vision-specific
domains. RESULTS: The intention-to-treat analysis demonstrated that the extended
model produced significantly better participation in life situations at
post-test when compared with the usual care only group. Gains were made
regardless of whether participants were, or were not, depressed at baseline. The
addition of the self-management group was also successful in significantly
reducing depression, increasing physical and mental health, generalised and
domain-specific self-efficacy, and adjustment to ARVL. With the exception of
adjustment and mental health, differences were still apparent at 12 weeks'
follow-up. CONCLUSION: Addition of self-management significantly improved
general health and vision-specific rehabilitation outcomes for older adults with
ARVL.

Publication Types:
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

PMID: 20139291  [PubMed - indexed for MEDLINE]

10: Br J Ophthalmol. 2010 Feb;94(2):170-3. 

Transcleral delivery of triamcinolone acetonide and ranibizumab to retinal
tissues using macroesis.

Singh RP, Mathews ME, Kaufman M, Riga A.

Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
singhr@ccf.org

AIM: To determine the feasibility of macroesis for the delivery of ranibizumab
and triamcinolone acetonide via a transcleral route. METHODS: Macroesis is a
non-invasive method of drug delivery that uses alternating current (AC) to
deliver drugs to target tissues. Two preclinical models of drug delivery were
used for feasibility studies of delivering ranibizumab and triamcinolone
acetonide to ocular tissues. In the first model, full-thickness sections of
rabbit ocular tissue (conjunctiva to retina) were placed on an interdigitated
electrode platform, and the drug was placed on the surface of the tissue. A
non-uniform electrical field was applied to the ocular tissue, and electrical
conductivity, a measurement of drug delivery, was monitored during the course of
the experiment. In a second model, termed a 'simulated vitreous model,' the same
full-thickness sections of rabbit ocular tissue were mounted below the electrode
device, and the test compounds were placed on the electrodes. The fluid below
the tissue, which simulated the vitreous cavity, was analysed using UV
spectroscopy at the end of the study for the presence of drug. RESULTS: In the
electrical conductivity studies, the electric characteristics of the tissue-drug
system clearly showed movement of the drug through the tissue to the dielectric
sensor based on changes in the electrical conductivity of the tissue sample with
triamcinolone. No change in tissue conductivity was observed when no drug was
placed. No heat generation occurred during the course of the study; nor was any
gross tissue destruction noted. In the simulated vitreous model, studies using
triamcinolone yielded concentrations ranging from 0.280 to 0.970 mg/ml,
depending on the voltage, frequency and time applied. In as little as 6.7 min,
clinically efficacious doses could be obtained in the preclinical system.
Studies using ranibizumab yielded concentrations of 0.070-0.171 mg/ml, depending
on the voltage, frequency, and time applied. In as little at 6.7 min, 92.8%
throughput could be achieved. CONCLUSION: Successful delivery of ranibizumab and
triamcinolone acetonide can be achieved with macroesis in preclinical studies.

PMID: 20139290  [PubMed - indexed for MEDLINE]

11: Br J Ophthalmol. 2010 Feb;94(2):167-9. 

Z-suture: a new knotless technique for transscleral suture fixation of
intraocular implants.

Szurman P, Petermeier K, Aisenbrey S, Spitzer MS, Jaissle GB.

University Eye Hospital, Centre of Ophthalmology, Eberhard-Karls University,
Tubingen, Germany.

The presented Z-suture is a simple, rapid and safe knotless technique that
facilitates transscleral suture fixation of various intraocular implants in the
ciliary sulcus, such as sutured intraocular lenses, artificial iris prostheses
and iris diaphragms. As the knotless approach reliably avoids suture erosion,
external fixation can be performed without any protecting scleral flaps or
lamellar grooves. The needle is simply passed through the sulcus and the
emerging polypropylene suture is secured in the sclera using a zigzag-shaped
intrascleral suture (Z-suture). Each pass starts directly adjacent to the
exiting site. Five passes are sufficient to reliably fix the suture so that it
resists even maximum tractive forces. Once this procedure is done, the suture
can be cut without any knot. By avoiding suture knots, and hence the need for
intrascleral flaps, this knotless approach may help to reduce suture-related
complications such as scleral atrophy, suture erosion and infections.

Publication Types:
    Evaluation Studies

PMID: 20139289  [PubMed - indexed for MEDLINE]

12: Br J Ophthalmol. 2010 Feb;94(2):143-5. 

Combination therapy with verteporfin and anti-VEGF agents in neovascular
age-related macular degeneration: where do we stand?

Kaiser PK.

Publication Types:
    Comment
    Editorial
    Research Support, Non-U.S. Gov't

PMID: 20139287  [PubMed - indexed for MEDLINE]